Go Pro
→ Trump's New Dollar (From Porter & Company) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
$15.40
+3.8%		$13.95
$5.03
▼
$26.95
$1.25B0.87816,707 shs843,289 shs
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
$4.79
+5.5%		$4.45
$1.93
▼
$12.46
$216.77M-0.1144,466 shs2.28 million shs
Savara Inc. stock logo
SVRA
Savara
$5.58
+3.9%		$5.68
$2.92
▼
$7.01
$1.10B0.291.64 million shs1.30 million shs
(Almost) Everything You Need To Know About The EV Market Cover
(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
-0.54%+0.68%-0.47%+21.66%+178.76%
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
+2.71%+5.09%+6.32%-9.74%+86.07%
Savara Inc. stock logo
SVRA
Savara
0.00%-3.59%-2.72%+5.71%+76.07%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
$15.40
+3.8%		$13.95
$5.03
▼
$26.95
$1.25B0.87816,707 shs843,289 shs
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
$4.79
+5.5%		$4.45
$1.93
▼
$12.46
$216.77M-0.1144,466 shs2.28 million shs
Savara Inc. stock logo
SVRA
Savara
$5.58
+3.9%		$5.68
$2.92
▼
$7.01
$1.10B0.291.64 million shs1.30 million shs
(Almost) Everything You Need To Know About The EV Market Cover
(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
-0.54%+0.68%-0.47%+21.66%+178.76%
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
+2.71%+5.09%+6.32%-9.74%+86.07%
Savara Inc. stock logo
SVRA
Savara
0.00%-3.59%-2.72%+5.71%+76.07%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
2.88
Moderate Buy$33.33116.45% Upside
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
1.75
Reduce$10.33115.73% Upside
Savara Inc. stock logo
SVRA
Savara
2.88
Moderate Buy$10.1481.77% Upside

Current Analyst Ratings Breakdown

Latest SVRA, NERV, and CRVS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/14/2026
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
Jefferies Financial Group Inc. logo
Jefferies Financial Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold ➝ Mixed$7.50 ➝ $10.00
8/12/2026
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeHold ➝ Strong Sell
7/30/2026
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
LADENBURG THALM/SH SH logo
LADENBURG THALM/SH SH
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong-Buy
7/28/2026
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
7/17/2026
Savara Inc. stock logo
SVRA
Savara
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
7/10/2026
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
6/24/2026
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
(Data available from 8/19/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
N/AN/A$0.13 per share117.00$2.68 per shareN/A
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
N/AN/AN/AN/A($4.47) per shareN/A
Savara Inc. stock logo
SVRA
Savara
N/AN/AN/AN/A$0.70 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
-$15.28M-$0.61N/AN/AN/AN/A-36.15%-33.62%11/3/2026 (Estimated)
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
-$293.42M-$28.87N/AN/AN/AN/AN/A-31.72%11/4/2026 (Estimated)
Savara Inc. stock logo
SVRA
Savara
-$118.84M-$0.58N/AN/AN/AN/A-90.28%-68.95%N/A

Latest SVRA, NERV, and CRVS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/11/2026Q2 2026
Savara Inc. stock logo
SVRA
Savara
-$0.1413-$0.16-$0.0188-$0.16$2.00 millionN/A
8/7/2026Q2 2026
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
-$0.1933-$0.14+$0.0533-$0.14N/AN/A
8/6/2026Q2 2026
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
-$0.1591-$0.19-$0.0309-$0.19N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
N/AN/AN/AN/AN/A
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
N/AN/AN/AN/AN/A
Savara Inc. stock logo
SVRA
Savara
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
N/A
16.16
16.16
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
N/A
20.15
20.14
Savara Inc. stock logo
SVRA
Savara
0.21
10.13
10.13

Institutional Ownership

CompanyInstitutional Ownership
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
46.64%
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
34.56%
Savara Inc. stock logo
SVRA
Savara
87.93%

Insider Ownership

CompanyInsider Ownership
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
19.70%
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
1.70%
Savara Inc. stock logo
SVRA
Savara
5.30%
CompanyEmployeesShares OutstandingFree FloatOptionable
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
3084.12 million67.55 millionOptionable
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
947.75 million46.94 millionNot Optionable
Savara Inc. stock logo
SVRA
Savara
20205.46 million194.57 millionOptionable

Recent News About These Companies

HC Wainwright Issues Negative Outlook for Savara Earnings
August 16 at 1:13 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30963133
Walleye Capital LLC Invests $1.53 Million in Savara Inc. $SVRA
August 15, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-walleye-capital-llc-invests-153-million-in-savara-inc-svra-2026-08-15/
What is HC Wainwright's Estimate for Savara FY2029 Earnings?
August 15, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30961881
Savara (NASDAQ:SVRA) Lowered to Sell Rating by Wall Street Zen
August 15, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30961531
Savara (NASDAQ:SVRA) Stock Rating Lowered by Wall Street Zen
August 15, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/savara-nasdaqsvra-stock-rating-lowered-by-wall-street-zen-2026-08-15/
HC Wainwright Brokers Lower Earnings Estimates for Savara
August 14, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/hc-wainwright-brokers-lower-earnings-estimates-for-savara-2026-08-14/
Savara (NASDAQ:SVRA) Stock Price Down 5.4% - What's Next?
August 13, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/savara-nasdaqsvra-stock-price-down-54-whats-next-2026-08-13/
HC Wainwright Has Pessimistic View of Savara FY2029 Earnings
August 13, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/hc-wainwright-has-pessimistic-view-of-savara-fy2029-earnings-2026-08-13/
Savara Reports Second Quarter 2026 Financial Results and Provides Business Update
August 11, 2026  |  caledonianrecord.comC
Savara (NASDAQ:SVRA) Releases Quarterly Earnings Results, Misses Expectations By $0.02 EPS
August 11, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/savara-nasdaqsvra-releases-quarterly-earnings-results-misses-expectations-by-002-eps-2026-08-11/
Savara (SVRA) to Post Earnings on Wednesday
August 11, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30953174
Savara Inc. $SVRA Shares Bought by Renaissance Technologies LLC
August 8, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-savara-inc-svra-shares-bought-by-renaissance-technologies-llc-2026-08-08/
Savara (SVRA) to Announce Quarterly Earnings on Wednesday
August 5, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/savara-svra-to-announce-quarterly-earnings-on-wednesday-2026-08-05/
Savara: High Potential Binary Bet Cruising To PDUFA After 3 Month Speed Bump
August 5, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4930599-savara-high-potential-binary-bet-cruising-to-pdufa-after-3-month-speed-bump
Seven Fleet Capital Management LP Grows Stock Holdings in Savara Inc. $SVRA
August 2, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-seven-fleet-capital-management-lp-grows-stock-holdings-in-savara-inc-svra-2026-08-02/
Savara Inc. (NASDAQ:SVRA) Receives Consensus Rating of "Moderate Buy" from Brokerages
July 30, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/savara-inc-nasdaqsvra-receives-consensus-rating-of-moderate-buy-from-brokerages-2026-07-30/
Savara Inc. $SVRA Shares Bought by Eversept Partners LP
July 28, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-savara-inc-svra-shares-bought-by-eversept-partners-lp-2026-07-28/
Orbimed Advisors LLC Acquires Shares of 635,000 Savara Inc. $SVRA
July 27, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-orbimed-advisors-llc-acquires-shares-of-635000-savara-inc-svra-2026-07-27/
Savara Inc. $SVRA Stock Position Boosted by Spruce Street Capital LP
July 25, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-savara-inc-svra-stock-position-boosted-by-spruce-street-capital-lp-2026-07-25/
Affinity Asset Advisors LLC Decreases Stock Holdings in Savara Inc. $SVRA
July 25, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-affinity-asset-advisors-llc-decreases-stock-holdings-in-savara-inc-svra-2026-07-25/
Savara (SVRA) Gets a Buy from Piper Sandler
July 24, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/SVRA-Q/pressreleases/3422910/savara-svra-gets-a-buy-from-piper-sandler/

New MarketBeat Followers Over Time

Media Sentiment Over Time

Corvus Pharmaceuticals stock logo

Corvus Pharmaceuticals NASDAQ:CRVS

$15.40 +0.57 (+3.84%)
Closing price 04:00 PM Eastern
Extended Trading
$15.37 -0.03 (-0.19%)
As of 07:40 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.

Minerva Neurosciences stock logo

Minerva Neurosciences NASDAQ:NERV

$4.79 +0.25 (+5.51%)
Closing price 04:00 PM Eastern
Extended Trading
$4.85 +0.06 (+1.34%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. The company has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.

Savara stock logo

Savara NASDAQ:SVRA

$5.58 +0.21 (+3.91%)
Closing price 04:00 PM Eastern
Extended Trading
$5.55 -0.03 (-0.57%)
As of 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Savara Inc., formerly Mast Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients. Molgradex is an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor. It is developing Molgradex for the treatment of autoimmune pulmonary alveolar proteinosis, a rare lung disease. AIR001 is a sodium nitrite solution for inhalation via nebulization. AIR001 is in Phase II clinical development for the treatment of heart failure with preserved ejection fraction, also known as diastolic heart failure or heart failure with preserved systolic function.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas